scholarly journals Non-invasive imaging of high-risk coronary plaque: the role of computed tomography and positron emission tomography

2020 ◽  
Vol 93 (1113) ◽  
pp. 20190740 ◽  
Author(s):  
Rong Bing ◽  
Krithika Loganath ◽  
Philip Adamson ◽  
David Newby ◽  
Alastair Moss
Keyword(s):  
Positron Emission Tomography ◽  
Molecular Imaging ◽  
Coronary Plaque ◽  
Emission Tomography ◽  
Plaque Morphology ◽  
Biological Processes ◽  
Non Invasive ◽  
Positron Emission

Despite recent advances, cardiovascular disease remains the leading cause of death globally. As such, there is a need to optimise our current diagnostic and risk stratification pathways in order to better deliver individualised preventative therapies. Non-invasive imaging of coronary artery plaque can interrogate multiple aspects of coronary atherosclerotic disease, including plaque morphology, anatomy and flow. More recently, disease activity is being assessed to provide mechanistic insights into in vivo atherosclerosis biology. Molecular imaging using positron emission tomography is unique in this field, with the potential to identify specific biological processes using either bespoke or re-purposed radiotracers. This review provides an overview of non-invasive vulnerable plaque detection and molecular imaging of coronary atherosclerosis.

scholarly journals Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Martin Thunemann ◽  
Barbara F. Schörg ◽  
Susanne Feil ◽  
Yun Lin ◽  
Jakob Voelkl ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Emission Tomography ◽  
Cell Populations ◽  
Specific Cell ◽  
Non Invasive ◽  
Positron Emission

scholarly journals Vulnerable plaque imaging using 18F-sodium fluoride positron emission tomography

2020 ◽  
Vol 93 (1113) ◽  
pp. 20190797 ◽  
Author(s):  
Jacek Kwiecinski ◽  
Piotr J Slomka ◽  
Marc R Dweck ◽  
David E Newby ◽  
Daniel S Berman
Keyword(s):  
Coronary Artery Disease ◽  
Positron Emission Tomography ◽  
Coronary Artery ◽  
Sodium Fluoride ◽  
Imaging Modality ◽  
Emission Tomography ◽  
Plaque Morphology ◽  
Non Invasive ◽  
Positron Emission ◽  
Artery Disease

Positron emission tomography (PET) with 18F-sodium fluoride (18F-NaF) has emerged as a promising non-invasive imaging modality to identify high-risk and ruptured atherosclerotic plaques. By visualizing microcalcification, 18F-NaF PET holds clinical promise in refining how we evaluate coronary artery disease, shifting our focus from assessing disease burden to atherosclerosis activity. In this review, we provide an overview of studies that have utilized 18F-NaF PET for imaging atherosclerosis. We discuss the associations between traditional coronary artery disease measures (risk factors) and 18F-NaF plaque activity. We also present the data on the histological validation as well as show how 18F-NaF uptake is associated with plaque morphology on intravascular and CT imaging. Finally, we discuss the technical challenges associated with 18F-NaF coronary PET highlighting recent advances in this area.

Expanding Role of Positron Emission Tomography in Cancer of the Uterine Cervix

2006 ◽  
Vol 4 (5) ◽  
pp. 463-469 ◽  
Author(s):  
Joseph G. Rajendran ◽  
Benjamin E. Greer
Keyword(s):  
Cervical Cancer ◽  
Positron Emission Tomography ◽  
Molecular Imaging ◽  
The United States ◽  
Emission Tomography ◽  
Cancer Center ◽  
Cellular Functions ◽  
Positron Emission ◽  
Oncology Practice

Molecular imaging through positron emission tomography (PET) is playing a very important role in the management of several different cancers. Its noninvasive nature and ability to study biologic function are ideal for oncology practice. PET is establishing itself in staging, guiding therapy, and follow-up of patients with cervical cancer. The emergence and widespread availability of combined PET/computed tomography technology has further consolidated the role of molecular scanning in managing these patients. This technology is now accessible to every cancer center in the United States and is also available in most countries. Although it is approved for staging patients with cervical cancer, its use in other clinical management situations is being evaluated. The real power of molecular imaging will be to predict treatment response and guide therapy and applications of novel PET tracers for studying complex cellular functions that characterize the tumor for individualized treatment approaches. Although PET technology is beyond the reach of many developing countries, the experience gained in major centers would help devise more effective and simpler treatments that can be introduced.

Molecular imaging of proliferation in vivo: Positron emission tomography with [18F]fluorothymidine

Methods ◽  
2009 ◽  
Vol 48 (2) ◽  
pp. 205-215 ◽  
Author(s):  
Andreas K. Buck ◽  
Ken Herrmann ◽  
Changxian Shen ◽  
Tobias Dechow ◽  
Markus Schwaiger ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Molecular Imaging ◽  
Emission Tomography ◽  
Positron Emission

scholarly journals PET and the multitracer concept in the study of neurodegenerative diseases

2015 ◽  
Vol 9 (4) ◽  
pp. 343-349 ◽  
Author(s):  
Henry Engler ◽  
Andres Damian ◽  
Cecilia Bentancourt
Keyword(s):  
Positron Emission Tomography ◽  
Molecular Imaging ◽  
Neurodegenerative Diseases ◽  
Brain Tissue ◽  
Neurodegenerative Disorders ◽  
Clinical Symptoms ◽  
Emission Tomography ◽  
Positron Emission ◽  
The Brain

ABSTRACT The complexity of the pathological reactions of the brain to an aggression caused by an internal or external noxa represents a challenge for molecular imaging. Positron emission tomography (PET) can indicate in vivo,anatomopathological changes involved in the development of different clinical symptoms in patients with neurodegenerative disorders. PET and the multitracer concept can provide information from different systems in the brain tissue building an image of the whole disease. We present here the combination of 18F-flourodeoxyglucose (FDG) and N-[11C-methyl]-L-deuterodeprenyl (DED), FDG and N-[11C-methyl] 2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PIB), PIB and L-[11C]-3'4-Dihydrophenylalanine (DOPA) and finally PIB and [15O]H2O.

Sign in / Sign up

Export Citation Format

Share Document